SITE013-0027

SITE013 (USA) › SITE013-0027

SITE013-0027

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2025-09-22

enrolled

AEs

5

Serious

2

Dropout signal

–

Adverse events

5

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-08 (study day 279); relationship: NOT RELATED; serious criteria: hospitalization

severe serious assessed

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-11-18 (study day 228); relationship: not assessed; serious criteria: hospitalization

severe serious assessed

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-08-22 (study day 140); relationship: not assessed

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-08 (study day 95); relationship: not assessed

mild assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-07-01 (study day 88); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.